411 related articles for article (PubMed ID: 9251109)
1. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy.
Kinoshita Y; Yokota A
NMR Biomed; 1997 Jan; 10(1):2-12. PubMed ID: 9251109
[TBL] [Abstract][Full Text] [Related]
2. Proton magnetic resonance spectroscopy of brain tumors: an in vitro study.
Kinoshita Y; Kajiwara H; Yokota A; Koga Y
Neurosurgery; 1994 Oct; 35(4):606-13; discussion 613-4. PubMed ID: 7808603
[TBL] [Abstract][Full Text] [Related]
3. Proton magnetic resonance spectroscopy of astrocytic tumors: an in vitro study.
Kinoshita Y; Kajiwara H; Yokota A; Koga Y
Neurol Med Chir (Tokyo); 1993 Jun; 33(6):350-9. PubMed ID: 7689180
[TBL] [Abstract][Full Text] [Related]
4. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy.
Poptani H; Gupta RK; Roy R; Pandey R; Jain VK; Chhabra DK
AJNR Am J Neuroradiol; 1995 Sep; 16(8):1593-603. PubMed ID: 7502961
[TBL] [Abstract][Full Text] [Related]
5. [Utility of proton magnetic resonance spectroscopy in the diagnosis of human brain tumors].
Yoshida Y; Yoshioka Y
No Shinkei Geka; 1991 May; 19(5):421-7. PubMed ID: 1852248
[TBL] [Abstract][Full Text] [Related]
6. 1H- and (31)P-MR spectroscopy of primary and recurrent human brain tumors in vitro: malignancy-characteristic profiles of water soluble and lipophilic spectral components.
Lehnhardt FG; Röhn G; Ernestus RI; Grüne M; Hoehn M
NMR Biomed; 2001 Aug; 14(5):307-17. PubMed ID: 11477651
[TBL] [Abstract][Full Text] [Related]
7. Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens.
Cheng LL; Chang IW; Louis DN; Gonzalez RG
Cancer Res; 1998 May; 58(9):1825-32. PubMed ID: 9581820
[TBL] [Abstract][Full Text] [Related]
8. Quantitative metabolite patterns of human brain tumors: detection by 1H NMR spectroscopy in vivo and in vitro.
Usenius JP; Kauppinen RA; Vainio PA; Hernesniemi JA; Vapalahti MP; Paljärvi LA; Soimakallio S
J Comput Assist Tomogr; 1994; 18(5):705-13. PubMed ID: 8089316
[TBL] [Abstract][Full Text] [Related]
9. Malignancy of brain tumors evaluated by proton magnetic resonance spectroscopy (1H-MRS) in vitro.
Czernicki Z; Horsztyński D; Jankowski W; Grieb P; Walecki J
Acta Neurochir Suppl; 2000; 76():17-20. PubMed ID: 11449999
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance spectroscopy detection of high lipid levels in intraaxial tumors without central necrosis: a characteristic of malignant lymphoma.
Yamasaki F; Takayasu T; Nosaka R; Amatya VJ; Doskaliyev A; Akiyama Y; Tominaga A; Takeshima Y; Sugiyama K; Kurisu K
J Neurosurg; 2015 Jun; 122(6):1370-9. PubMed ID: 25748300
[TBL] [Abstract][Full Text] [Related]
11. [Contribution of magnetic resonance spectrometry to the diagnosis of intracranial tumors].
Galanaud D; Nicoli F; Le Fur Y; Roche P; Confort-Gouny S; Dufour H; Ranjeva JP; Peragut JC; Viout P; Cozzone PJ
Ann Med Interne (Paris); 2002 Dec; 153(8):491-8. PubMed ID: 12610422
[TBL] [Abstract][Full Text] [Related]
12. Potential of MR spectroscopy for assessment of glioma grading.
Bulik M; Jancalek R; Vanicek J; Skoch A; Mechl M
Clin Neurol Neurosurg; 2013 Feb; 115(2):146-53. PubMed ID: 23237636
[TBL] [Abstract][Full Text] [Related]
13. In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard.
Tong Z; Yamaki T; Harada K; Houkin K
Magn Reson Imaging; 2004 Sep; 22(7):1017-24. PubMed ID: 15288143
[TBL] [Abstract][Full Text] [Related]
14. Proton MR spectroscopy in patients with neurofibromatosis type 1: evaluation of hamartomas and clinical correlation.
Castillo M; Green C; Kwock L; Smith K; Wilson D; Schiro S; Greenwood R
AJNR Am J Neuroradiol; 1995 Jan; 16(1):141-7. PubMed ID: 7900583
[TBL] [Abstract][Full Text] [Related]
15. [Proton magnetic resonance spectroscopy (1H-MRS) for the diagnosis of brain tumors and the evaluation of treatment].
Grand S; Tropres I; Hoffmann D; Ziegler A; Le Bas JF
Neurochirurgie; 2005 Sep; 51(3-4 Pt 2):299-308. PubMed ID: 16292174
[TBL] [Abstract][Full Text] [Related]
16. In vivo proton magnetic resonance spectroscopy of brain tumors.
Fountas KN; Kapsalaki EZ; Gotsis SD; Kapsalakis JZ; Smisson HF; Johnston KW; Robinson JS; Papadakis N
Stereotact Funct Neurosurg; 2000; 74(2):83-94. PubMed ID: 11251398
[TBL] [Abstract][Full Text] [Related]
17. Cho/Cr ratio at MR spectroscopy as a biomarker for cellular proliferation activity and prognosis in glioma: correlation with the expression of minichromosome maintenance protein 2.
Gao W; Wang X; Li F; Shi W; Li H; Zeng Q
Acta Radiol; 2019 Jan; 60(1):106-112. PubMed ID: 29665708
[TBL] [Abstract][Full Text] [Related]
18. In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard.
Tong Z; Yamaki T; Harada K; Houkin K
Magn Reson Imaging; 2004 Jun; 22(5):735-42. PubMed ID: 15172069
[TBL] [Abstract][Full Text] [Related]
19. Proton magnetic resonance spectroscopy and intracranial tumours: clinical perspectives.
Falini A; Calabrese G; Origgi D; Lipari S; Triulzi F; Losa M; Scotti G
J Neurol; 1996 Oct; 243(10):706-14. PubMed ID: 8923303
[TBL] [Abstract][Full Text] [Related]
20. Contrast/Noise ratio on conventional MRI and choline/creatine ratio on proton MRI spectroscopy accurately discriminate low-grade from high-grade cerebral gliomas.
Fayed N; Morales H; Modrego PJ; Pina MA
Acad Radiol; 2006 Jun; 13(6):728-37. PubMed ID: 16679275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
